BioCardia, Inc. issued a press release on June 18, 2026, providing a business strategy update and highlighting business development opportunities. BioCardia, Inc. is a biotechnology company focused on developing and delivering cell therapy products.

BioCardia, Inc. announced that following a recent share sale via an "At The Market" offering agreement with H.C. Wainwright & Co., the company has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement. Between April 1, 2026, and June 5, 2026, the company sold 4,004,330 shares at an average price of $1.27, generating $4.9 million in net proceeds. BioCardia, Inc. is a biotechnology company focused on developing cardiovascular therapies.

BioCardia, Inc. announced in a press release that it sold 3,509,604 shares of common stock at an average price of $1.279 per share on June 5, 2026, pursuant to its "At The Market" offering agreement with H.C. Wainwright & Co.